Equities

Cenra Inc

3716:TAI

Cenra Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)37.90
  • Today's Change-0.10 / -0.26%
  • Shares traded75.22k
  • 1 Year change-19.36%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Cenra Inc's net income fell -32.51% from 477.54m to 322.29m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 26.88% to 28.26%.
Gross margin37.10%
Net profit margin4.18%
Operating margin4.03%
Return on assets2.97%
Return on equity5.02%
Return on investment4.29%
More ▼

Cash flow in TWDView more

In 2023, Cenra Inc did not generate a significant amount of cash. However, the company earned 601.91m from its operations for a Cash Flow Margin of 7.02%. In addition the company used 332.44m on investing activities and also paid 247.14m in financing cash flows.
Cash flow per share2.78
Price/Cash flow per share7.83
Book value per share50.26
Tangible book value per share50.17
More ▼

Balance sheet in TWDView more

Cenra Inc has a Debt to Total Capital ratio of 29.76%, a higher figure than the previous year's 19.17%.
Current ratio1.36
Quick ratio0.7054
Total debt/total equity0.426
Total debt/total capital0.2976
More ▼

Growth rates in TWD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -37.50% and -32.31%, respectively. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)1.62%
Div growth rate (5 year)-8.97%
Payout ratio (TTM)40.09%
EPS growth(5 years)-2.81
EPS (TTM) vs
TTM 1 year ago
41.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.